The Coordination and Admissions Committee of the Mercado Alternativo Bursátil (MAB) has submitted to the Board of Directors a favourable report on Atrys Health,stating that the company is eligible for admission to the market’s Growth Companies segment following a thorough review of all the information presented by the company.
Prior to its listing on MAB, which requires the final approval of MAB’s Board of Directors, the company will carry out a public share offering.
Atrys Health’s Informative Document is available on www.bolsasymercados.es/mab, where all the information about the company and its activities can be found.
NORGESTION is acting as Registered Adviser and Banco Sabadell as Liquidity Provider.
Atrys Health aims to offer its patients personalised therapies as well as the development of new therapeutical treatments and diagnosis tools. It has operations in America and Europe, with clients in 7 countries, namely the US, Switzerland, United Kingdom, Germany, Denmark, Portugal and Spain.